Health
Cancer Prevention
2015 IPO

Interpace Diagnostics

$0.70
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.0136 (-1.91%) Today
+$0.0002 (0.03%) After Hours

Why Robinhood?

You can buy or sell IDXG and other stocks, options, ETFs, and crypto commission-free!

About

Interpace Diagnostics Group, Inc. operates as an bioinformatics company, which engages in the development and commercialization of molecular diagnostic test and pathology services. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment; ThyGenX and PathFinderTG which assesses thyroid nodules for risk of malignancy; and ThyraMIR, which assesses thyroid nodules for risk of malignancy utilizing a proprietary gene expression assay. Read More The company was founded by John P. Dugan in 1987 and is headquartered in Parsippany, NJ.

Employees
89
Headquarters
Parsippany, New Jersey
Founded
1986
Market Cap
20.47M
Price-Earnings Ratio
Dividend Yield
Average Volume
407.85K
High Today
$0.72
Low Today
$0.675
Open Price
$0.72
Volume
109.33K
52 Week High
$1.78
52 Week Low
$0.6729

Collections

Health
Cancer Prevention
2015 IPO
US
North America

News

Seeking AlphaMay 14

Interpace Diagnostics Group, Inc. CEO Jack Stover on Q1 2019 Results - Earnings Call Transcript

Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) Q1 2019 Earnings Conference Call May 13, 2019 4:30 PM ET Company Participants Jack Stover - President & CEO Jim Early - CFO Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Yi Chen - H.C. Wainwright Benjamin Haynor - Alliance Global Partners Naureen Quibria - Maxim Group François Brisebois - LaidLaw Capital Markets Operator Greetings, and welcome to the Interpace Diagnostics Group First Quarter 2019 Financial Results Conference Call. ...

172
Yahoo FinanceMay 13

Interpace Diagnostics Reports First Quarter 2019 Financial Results and Provides Business Update

Quarterly Revenue Grew to $6.0 Million, a 25% Increase Year-over-Year Annual 2019 Revenue Guidance of $27 to $28 Million, a 25% Increase Conference Call and Webcast Monday May 13, 2019 at 4:30 pm ET Parsippany, NJ, May 13, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (IDXG), a fully integrated bioinformatics and commercial molecular diagnostic company, today announced financial results for the first quarter ended March 31, 2019, and reviewed recent business progress. “We had a strong start...

90
NasdaqMay 9

Interpace Diagnostics BarreGEN® Data to be Presented at Digestive Disease Week

Company to Host Fellowship and Key Opinion Leader Programs PARSIPPANY, NJ, May 09, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) announced today that data from an independent study, which showed that BarreGEN® performed effectively as a biomarker tool for predicting risk of developing more advanced stages of disease prior to visible appearance of advanced histology, will be presented at the annual Digestive Disease Week® ("DDW"). The meeting will be held in San Diego, CA on...

138

Earnings

-$0.11
-$0.09
-$0.08
-$0.06
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
-$0.06 per share
Actual
-$0.10 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.